Phase 1 study of dry eye solution launched

Article

Novaliq GmbH is launching a Phase 1 study of its 0.05% clear cyclosporine solution (CyclASol) following European and US patent approval of the solution for the treatment of dry eye syndrome.

Novaliq GmbH is launching a Phase 1 study of its 0.05% clear cyclosporine solution (CyclASol) following European and US patent approval of the solution for the treatment of dry eye syndrome.

CyclASol was developed from EyeSol, Novaliq's broad range semi-fluorinated alkane (SFA) drug delivery platform. Novaliq says the platform offers significant benefits for delivery of ophthalmological drugs, primarily by enhancing the therapeutic effect of poorly soluble drugs.

According to Novaliq, CyclASol has demonstrated long-term stability and wettability, pharmacokinetics, and biocompatibility superior to that of conventional emulsion formulations of cyclosporine. CyclASol is available in multidose and preservative-free bottles.

"We are pleased to receive the US and European patent and to announce the start of a Phase 1 CyclASol study," Bernhard Günther, CEO of Novaliq GmbH, said. "These are both significant new milestones for Novaliq as we build our innovative drug delivery portfolio."

"We congratulate Novaliq on obtaining patent approval for CyclASol and the start of their clinical trials," said Mathias Hothum, managing director of investment company Dievini Hopp BioTech Holding GmbH & Co. KG. "We are pleased to support Novaliq as it pioneers new topical ocular drug delivery technology. We endorse Novaliq's strategy to establish a portfolio of consumer and prescription product portfolios within ophthalmology."

For more information, visit www.novaliq.de or e-mail: info@novaliq.de.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.